Experience:
No experience
Employment Type:
Intern/Co-op
Posted:
10/20/2019
Job Category:
Accounting
Co-op Intern-Cost Accounting
(This job is no longer available)
loading
loading
School
Major
Grad Date
 
 

Not sure what types of jobs you are interested in?


Explore Jobs
Based on Your Education

Follow This Company
Share

Job Description

Job Description

Co-op Intern-Cost Accounting

The Vertex Co-Op Program offers students the opportunity to learn about the pharmaceutical industry from a hands-on perspective. You will be working closely with and learning from some of the brightest people in the industry. When you join our internship program you should not be surprised to see that our environment is one that is innovative and team oriented, where collaboration is not just a word, and "we are fearless" is in everything we do. Students can expect to be challenged by their summer project plan, connect with other interns, and feel valued by the Vertex community. Not only will interns learn about their day-to-day tasks through their specific work assignments, but they will interact and have exposure to our organizational leaders and their teams through a series of Professional Development Workshops.

Be FEARLESS... Join us and help kick start the path to your career!

Co-op Program: 6 Month Commitment (January - June 2020), Full Time, 40 Hours/Week

Job Description:

The Cost Accounting Intern concentrates on accounting and analysis for inventory standard costs, variances, reserves and cost of goods. The Intern partners with our Supply Chain Management team and other stakeholders throughout the company. This position provides exposure to key accounting and financial reporting areas, offering development opportunities that can lead to advanced roles within the Finance organization or within other departments.

Vertex is actively seeking a Cost Accounting Intern in the Supply Chain Accounting/Finance group to perform product costing and inventory accounting for the Company's existing products as well as future products sold in the U.S. and internationally. The Cost Accounting Intern concentrates on accounting and analysis for inventory standard costs, variances, reserves and cost of goods. The Intern partners with our Supply Chain Management team and other stakeholders throughout the company. This position provides exposure to key accounting and financial reporting areas, offering development opportunities that can lead to advanced roles within the Finance organization or within other departments.

Key Responsibilities:

* Supports accounting for pharmaceutical products as relates to inventory and cost of goods
* Collaborates across Supply Chain and Finance to monitor inventory during the production and delivery cycle
* Updates cost models for month close which include Manufacturing Variances and Uninvoiced Receipts
* Prepares journal entries to support month end financial close deliverables
* Reconciles and analyzes key balance sheet and income statement accounts
* Ensures SOX Compliance for responsible area, including implementing improvements to improve the efficiency of current controls
* Conducts physical inventory audits, as required

Minimum Qualifications

Minimum Qualifications

* Working toward Bachelor's degree in Accounting or Finance, or related discipline

Preferred Qualifications:

* Strong/Advanced Excel skills
* Strong communication and organizational skills
* Self-motivated individual with strong problem solving and analytical skills
* Sound understanding of accounting principles
* Proven ability to multi-task and work independently in a challenging fast paced environment
* "Go getter" attitude with drive to learn and advance

About Vertex Pharmaceuticals, Inc

Vertex Pharmaceuticals Incorporated (Vertex) is engaged in the business of discovering, developing and commercializing small molecule drugs for the treatment of serious diseases. Telaprevir, the Company’s principal drug candidate, is an oral hepatitis C protease inhibitor and an antiviral treatment in clinical development that targets hepatitis C virus (HCV) infection. As of December 31, 2008, Vertex was also developing, among other compounds, VX-770, a drug candidate for the treatment of patients with cystic fibrosis (CF). In March 2009, the Company completed its acquisition of ViroChem Pharma Inc., a company with two investigational HCV polymerase inhibitors in clinical development.